interesting, though, that inspection of the immunoblot data provided by Li et al. reveals that in one case the serum reacts with a 180-kDa protein, which is compatible with BPAG2, and subsequent work 7 found that sera of patients with bullous pemphigoid with neurological disease reacted with both 230and 180-kDa antigens in human brain extract, corresponding to BPAG1 and BPAG2, respectively. Also, in a reply to Foureur et al., 8 Wieland et al. 9 specify that in their study of BPAG2 and BPAG1 autoantibodies in the serum of 337 individuals with no signs of bullous pemphigoid, of the 25 found to be positive, five had neurological diseases listed in their medical records. In all but one case, the amount of BPAG2 antibodies, as measured with enzyme-linked immunosorbent assay, was greater than that of BPAG1. These findings underline the possibility that BPAG2, the primary autoantigen in bullous pemphigoid, 10 could also be a common aetiopathogenetic denominator in the dermatological and neurological disorders, feasibly in addition to BPAG1.
A.O. SEPPÄ N E N